Efficacy and safety of zanubrutinib versus rituximab-based chemoimmunotherapy in Waldenström macroglobulinemia (WM): Matching-adjusted indirect comparisons.
Jorge J. Castillo(Dana-Farber Cancer Institute), Boxiong Tang, Qian Zhao(Shanghai Open University), Rongzhe Liu(Pharmerit (United States)), Xīn Gào(Qingdao University), Yu Wang(China-Japan Friendship Hospital), Aileen Cohen(Düsseldorf University Hospital), Todd M. Zimmerman(Broad Institute), Keri Yang(Universidad San Carlos)
Cited by 2
Related Papers
Aberrant CpG-island methylation has non-random and tumour-type–specific patterns
|Nature Genetics|2000|1.4k
Widespread Genetic Heterogeneity in Multiple Myeloma: Implications for Targeted Therapy
|Cancer Cell|2014|1k
Ibrutinib in Previously Treated Waldenström’s Macroglobulinemia
|New England Journal of Medicine|2015|937
Zanubrutinib or Ibrutinib in Relapsed or Refractory Chronic Lymphocytic Leukemia
|New England Journal of Medicine|2022|453
Essential requirement for two-pore channel 1 in NAADP-mediated calcium signaling
|The Journal of Cell Biology|2009|406